100,284 Shares in GeneDx Holdings Corp. $WGS Bought by Capital International Investors

Capital International Investors acquired a new position in GeneDx Holdings Corp. (NASDAQ:WGS) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 100,284 shares of the company’s stock, valued at approximately $10,805,000. Capital International Investors owned 0.35% of GeneDx as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in WGS. Royal Bank of Canada grew its stake in shares of GeneDx by 30.2% during the 1st quarter. Royal Bank of Canada now owns 29,479 shares of the company’s stock valued at $2,611,000 after acquiring an additional 6,840 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in GeneDx by 6.3% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 7,641 shares of the company’s stock worth $677,000 after acquiring an additional 453 shares during the period. NewEdge Advisors LLC lifted its holdings in GeneDx by 270,700.0% during the first quarter. NewEdge Advisors LLC now owns 2,708 shares of the company’s stock valued at $240,000 after purchasing an additional 2,707 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of GeneDx by 67.5% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 28,224 shares of the company’s stock worth $2,500,000 after purchasing an additional 11,375 shares during the period. Finally, Envestnet Asset Management Inc. boosted its position in shares of GeneDx by 63.9% in the second quarter. Envestnet Asset Management Inc. now owns 14,942 shares of the company’s stock worth $1,379,000 after purchasing an additional 5,823 shares during the period. Hedge funds and other institutional investors own 61.72% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the company. Jefferies Financial Group set a $150.00 price target on GeneDx in a report on Monday, February 23rd. Weiss Ratings reaffirmed a “sell (d)” rating on shares of GeneDx in a research note on Wednesday, January 21st. Wells Fargo & Company upgraded GeneDx from an “equal weight” rating to an “overweight” rating and set a $155.00 target price for the company in a research report on Monday, February 9th. Piper Sandler reissued an “overweight” rating and set a $130.00 target price (down from $160.00) on shares of GeneDx in a research note on Tuesday, February 24th. Finally, Canaccord Genuity Group upped their price target on GeneDx from $160.00 to $170.00 and gave the stock a “buy” rating in a research note on Monday, December 22nd. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, GeneDx presently has a consensus rating of “Moderate Buy” and an average target price of $150.71.

GeneDx Trading Down 9.7%

WGS stock opened at $76.85 on Friday. GeneDx Holdings Corp. has a twelve month low of $55.17 and a twelve month high of $170.87. The stock has a market capitalization of $2.25 billion, a price-to-earnings ratio of -102.47 and a beta of 2.03. The company has a quick ratio of 2.34, a current ratio of 2.46 and a debt-to-equity ratio of 0.16. The firm’s fifty day simple moving average is $97.36 and its two-hundred day simple moving average is $121.15.

GeneDx (NASDAQ:WGS) last released its earnings results on Monday, February 23rd. The company reported $0.14 EPS for the quarter, beating analysts’ consensus estimates of $0.11 by $0.03. GeneDx had a positive return on equity of 14.73% and a negative net margin of 4.92%.The firm had revenue of $120.99 million for the quarter, compared to analysts’ expectations of $120.80 million. As a group, analysts anticipate that GeneDx Holdings Corp. will post 0.97 earnings per share for the current year.

Insider Transactions at GeneDx

In related news, CFO Kevin Feeley sold 6,187 shares of the firm’s stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $78.61, for a total transaction of $486,360.07. Following the sale, the chief financial officer owned 18,674 shares of the company’s stock, valued at $1,467,963.14. This trade represents a 24.89% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Katherine Stueland sold 25,459 shares of GeneDx stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $78.61, for a total transaction of $2,001,331.99. Following the completion of the transaction, the chief executive officer directly owned 38,683 shares in the company, valued at approximately $3,040,870.63. The trade was a 39.69% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 57,702 shares of company stock valued at $5,640,255. Company insiders own 29.60% of the company’s stock.

About GeneDx

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.